Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Short-Term Tropisetron Treatment and Cognitive and P50 Auditory Gating Deficits in Schizophrenia
Xiangyang Zhang, Lei Liu, Shaowen Liu, et al.
American Journal of Psychiatry (2012) Vol. 169, Iss. 9, pp. 974-981
Closed Access | Times Cited: 76

Showing 1-25 of 76 citing articles:

Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology
Thomas R. E. Barnes, Richard Drake, Carol Paton, et al.
Journal of Psychopharmacology (2019) Vol. 34, Iss. 1, pp. 3-78
Open Access | Times Cited: 513
The serotonergic system and cognitive function
Dubravka Švob Štrac, Nela Pivac, Dorotea Mück‐Šeler
Translational Neuroscience (2016) Vol. 7, Iss. 1, pp. 35-49
Open Access | Times Cited: 240
Reversal of cognitive decline: A novel therapeutic program
Dale E. Bredesen
Aging (2014) Vol. 6, Iss. 9, pp. 707-717
Open Access | Times Cited: 215
Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia
Maren Carbon, Christoph U. Correll
CNS Spectrums (2014) Vol. 19, Iss. S1, pp. 35-53
Closed Access | Times Cited: 214
The human CHRNA7 and CHRFAM7A genes: A review of the genetics, regulation, and function
Melissa L. Sinkus, Sharon Graw, Robert Freedman, et al.
Neuropharmacology (2015) Vol. 96, pp. 274-288
Open Access | Times Cited: 156
α7-Nicotinic Acetylcholine Receptor Agonists for Cognitive Enhancement in Schizophrenia
Robert Freedman
Annual Review of Medicine (2013) Vol. 65, Iss. 1, pp. 245-261
Closed Access | Times Cited: 154
Intrinsic Hippocampal Activity as a Biomarker for Cognition and Symptoms in Schizophrenia
Jason R. Tregellas, Jason Smucny, Josette G. Harris, et al.
American Journal of Psychiatry (2014) Vol. 171, Iss. 5, pp. 549-556
Open Access | Times Cited: 142
Therapeutic Potential ofα7 Nicotinic Acetylcholine Receptors
Daniel Bertrand, Chih-Hung L. Lee, Dorothy G. Flood, et al.
Pharmacological Reviews (2015) Vol. 67, Iss. 4, pp. 1025-1073
Open Access | Times Cited: 130
Evaluating the role of the alpha-7 nicotinic acetylcholine receptor in the pathophysiology and treatment of schizophrenia
Jared W. Young, Mark A. Geyer
Biochemical Pharmacology (2013) Vol. 86, Iss. 8, pp. 1122-1132
Open Access | Times Cited: 121
5-HT3Receptor Antagonists in Neurologic and Neuropsychiatric Disorders: The Iceberg Still Lies beneath the Surface
Gohar Fakhfouri, Reza Rahimian, Jonas Dyhrfjeld‐Johnsen, et al.
Pharmacological Reviews (2019) Vol. 71, Iss. 3, pp. 383-412
Open Access | Times Cited: 88
nAChR dysfunction as a common substrate for schizophrenia and comorbid nicotine addiction: Current trends and perspectives
Vinay Parikh, Munir Gunes Kutlu, Thomas J. Gould
Schizophrenia Research (2016) Vol. 171, Iss. 1-3, pp. 1-15
Open Access | Times Cited: 86
α7 nicotinic acetylcholine receptors as therapeutic targets in schizophrenia: Update on animal and clinical studies and strategies for the future
Alvin V. Terry, Patrick M. Callahan
Neuropharmacology (2020) Vol. 170, pp. 108053-108053
Open Access | Times Cited: 72
Therapeutic Targeting of α7 Nicotinic Acetylcholine Receptors
Roger L. Papke, Nicole A. Horenstein
Pharmacological Reviews (2021) Vol. 73, Iss. 3, pp. 1118-1149
Open Access | Times Cited: 58
Efficacy of different types of cognitive enhancers for patients with schizophrenia: a meta-analysis
Igne Sinkeviciute, Marieke J.H. Begemann, Merel Prikken, et al.
Schizophrenia (2018) Vol. 4, Iss. 1
Open Access | Times Cited: 79
Nicotinic Mechanisms in the Treatment of Psychotic Disorders: A Focus on the α7 Nicotinic Receptor
Ann Olincy, Robert Freedman
Handbook of experimental pharmacology (2012), pp. 211-232
Open Access | Times Cited: 78
Alpha7 Nicotinic Receptors as Therapeutic Targets in Schizophrenia
Jason R. Tregellas, Korey P. Wylie
Nicotine & Tobacco Research (2018) Vol. 21, Iss. 3, pp. 349-356
Open Access | Times Cited: 74
Alpha-7 nicotinic agonists for cognitive deficits in neuropsychiatric disorders: A translational meta-analysis of rodent and human studies
Alan S. Lewis, Gerrit I. van Schalkwyk, Michael H. Bloch
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2017) Vol. 75, pp. 45-53
Open Access | Times Cited: 73
The past and future of novel, non-dopamine-2 receptor therapeutics for schizophrenia: A critical and comprehensive review
Ragy R. Girgis, Anthony W. Zoghbi, Daniel C. Javitt, et al.
Journal of Psychiatric Research (2018) Vol. 108, pp. 57-83
Closed Access | Times Cited: 68
First in human trial of a type I positive allosteric modulator of alpha7-nicotinic acetylcholine receptors: Pharmacokinetics, safety, and evidence for neurocognitive effect of AVL-3288
Kelvin W. Gee, Ann Olincy, Richard E. Kanner, et al.
Journal of Psychopharmacology (2017) Vol. 31, Iss. 4, pp. 434-441
Open Access | Times Cited: 53
Selective 5HT3 antagonists and sensory processing: a systematic review
Eirini Tsitsipa, Jonathan Rogers, Sebastian Casalotti, et al.
Neuropsychopharmacology (2022) Vol. 47, Iss. 4, pp. 880-890
Open Access | Times Cited: 25
Targeting of α7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia and the Use of Auditory Sensory Gating as a Translational Biomarker
Kenji Hashimoto
Current Pharmaceutical Design (2015) Vol. 21, Iss. 26, pp. 3797-3806
Open Access | Times Cited: 49
Tropisetron and its targets in Alzheimer’s disease
Kenji Hashimoto
Expert Opinion on Therapeutic Targets (2014) Vol. 19, Iss. 1, pp. 1-5
Open Access | Times Cited: 48
Tropisetron sensitizes α7 containing nicotinic receptors to low levels of acetylcholine in vitro and improves memory-related task performance in young and aged animals
Patrick M. Callahan, Daniel Bertrand, Sonia Bertrand, et al.
Neuropharmacology (2017) Vol. 117, pp. 422-433
Closed Access | Times Cited: 41
Cognitive Enhancers in Schizophrenia: A Systematic Review and Meta-Analysis of Alpha-7 Nicotinic Acetylcholine Receptor Agonists for Cognitive Deficits and Negative Symptoms
María Recio-Barbero, Rafael Segarra, Arantzazu Zabala, et al.
Frontiers in Psychiatry (2021) Vol. 12
Open Access | Times Cited: 30
Potential serotonergic agents for the treatment of schizophrenia
Ricardo P. Garay, Michel Bourin, Evelyne de Paillette, et al.
Expert Opinion on Investigational Drugs (2015) Vol. 25, Iss. 2, pp. 159-170
Closed Access | Times Cited: 39
Page 1 - Next Page

Scroll to top